Sarcoidosis in patients with chronic hepatitis C virus infection: analysis of 68 cases.
We describe the clinical characteristics, the patterns of association, and the role of antiviral therapies in patients with sarcoidosis associated with chronic hepatitis C virus (HCV) infection. Sixty-eight patients were included in the current study, 56 cases identified in the literature search plus 12 unpublished cases from our department. In 50 HCV patients, sarcoidosis appeared after starting antiviral therapy. Antiviral therapy associated with triggered sarcoidosis consisted of alpha-interferon monotherapy in 20 cases and combined therapy with alpha-interferon and ribavirin in 30. Sarcoidosis appeared during the first 6 months after starting therapy in 66% of patients. The clinical picture of sarcoidosis included predominantly pulmonary disease in 38 (76%) patients and cutaneous sarcoidosis in 30 (60%). Antiviral therapy was discontinued in 60% of patients and continued or adjusted in 14%, while sarcoidosis appeared after completed therapy in the remaining cases. Specific therapy for sarcoidosis was started in only 21 patients, mainly with oral corticosteroids. The outcome of patients was detailed in 46 cases: remission or improvement was observed in 38/46 (83%) patients, stabilization of sarcoidosis in 5/46 (11%), and reactivation of sarcoidosis after an initial improvement in 3/46 (6%). Finally, 18 treatment-naive HCV patients presented sarcoidosis, with 14/18 (87%) patients presenting with pulmonary involvement and 8/18 (44%) with cutaneous involvement. In summary, sarcoidosis may be observed in HCV patients in 2 different situations: triggered by antiviral therapy (in 75% of cases) and unrelated to treatment. Sarcoidosis during antiviral therapy may present mainly as cutaneous or pulmonary disease, with a benign, uncomplicated evolution in more than 85% of cases. However, more complicated cases are observed, especially in HCV patients with preexisting sarcoidosis and/or with previous antiviral treatment. Clinicians should be aware of the possibility that sarcoidosis may initially manifest or be reactivated during or shortly after treatment with antiviral therapy in patients with chronic HCV infection.
Ramos-Casals
Manuel
M
From Departments of Autoimmune Diseases (MR-C, NN, PB-Z, RC, JF), Pneumology (AX), and Liver Unit (JMS-T), Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), School of Medicine, University of Barcelona, Barcelona and Department of Internal Medicine (JM), Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain.
Mañá
Juan
J
Nardi
Norma
N
Brito-Zerón
Pilar
P
Xaubet
Antoni
A
Sánchez-Tapias
José Maria
JM
Cervera
Ricard
R
Font
Josep
J
D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D012254:Ribavirin / Q000009:adverse effects; D012507:Sarcoidosis / Q000139:chemically induced / Q000150:complications* / Q000188:drug therapy; D012871:Skin Diseases / Q000139:chemically induced / Q000150:complications* / Q000188:drug therapy
D000998:Antiviral Agents; D005938:Glucocorticoids; D016898:Interferon-alpha; D012254:Ribavirin; D011241:Prednisone